Lytix Biopharma ASA · OSL:LYTIX

Lytix Biopharma ASA — Q1 2023 Earnings Presentation

22 slides from Lytix Biopharma ASA's earnings presentation, May 11, 2023

  1. Slide 1: Lytix Biopharma AS First quarter 2023 presentation

    Lytix Biopharma AS New class of immunotherapy First quarter 2023 presentation May 11, 2023

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person

  3. Slide 3: Presenting team

    Presenting team Øystein Rekdal / CEO and co-founder • Dr. Rekdal’s post-doctoral research forms the basis of Lytix Biopharma’s oncolytic molecule platform. • Over the last years Rekdal has been instrumental in the development of intra-tumoral therapy of LTX-315 from preclinical to clinical ‘proof of

  4. Slide 4: Scientifically and commercially validated

    Scientifically and commercially validated Unique non-viral oncolytic platform with broad pipeline opportunities Innovative pipeline that overcomes major • Lead candidate; one completed challenges in cancer therapy and two ongoing Phase II studies • Tumor heterogeneity • Second generation molecule: •

  5. Slide 5: Highlights for the first quarter

    Highlights for the first quarter ATLAS-IT-05 Countries with active sites ‒ All six sites in Europe are now open and actively recruiting patients ‒ One new site in the US opened during the quarter – UPMC Hillman Cancer Center Verrica Pharmaceuticals has completed treatment in part 1 of three parts of

  6. Slide 6: Post period events

    Post period events Following the positive safety assessment and promising signs of activity from Part 1 of the study, Verrica advanced into the second part of their ongoing Phase 2 study in basal cell carcinoma in April 2023 At Lytix’ Annual General Meeting, Marie Roskrow was elected as new Chairper

  7. Slide 7: Clinical/Operational update

    Clinical/Operational update

  8. Slide 8: ATLAS-IT-05 - heading for complete recruitment

    ATLAS-IT-05 - heading for complete recruitment The clinical trial application approved under EU`s clinical trial regulation ‒ Six sites are active in Norway, Spain and France ‒ Three sites are active in the US and a fourth site is close to opening ‒ The sites are recognized for intratumoral immunoth

  9. Slide 9: Verrica Pharmaceuticals - Phase II study in good progress

    Verrica Pharmaceuticals - Phase II study in good progress Verrica has completed treatment in part 1 of three parts of their ongoing Phase II study evaluating LTX-315 in basal cell carcinoma (BCC) Part 2 of the Phase II trial started in April 2023 and will further explore dosing regimens allowing ide

  10. Slide 10: LTX-401 - Lytix' next generation oncolytic molecule

    LTX-401 - Lytix` next generation oncolytic molecule Activities progressing as planned to submit a Clinical Trial Application to start a Phase I study Liver cancers represent large cancer segments with high unmet medical need and modest effect with checkpoint inhibitors LTX-401 may solve the high unm

  11. Slide 11: Pipeline

    Pipeline Product Description Indication Discovery Preclinical Phase I Phase II Phase III candidate ATLAS-IT-05 Melanoma patients Pembrolizumab progressed on (Keytruda®) checkpoint inhibitors Phase II by Verrica LTX-315 Pharmaceuticals Basal cell carcinoma (monotherapy) ATLAS-IT-04 Advanced soft tiss

  12. Slide 12: Key figures

    Key figures

  13. Slide 13: Key figures – profit and loss

    Key figures – profit and loss Unaudited Unaudited Amounts in NOK thousands Q1 2023 Q1 2022 FY 2022 Total operating income 375 1,509 17,273 Total operating expenses (24,846) (16,182) (82,968) Loss from operations (24,471) (14,673) (65,695) Loss for the period (19,673) (15,231) (56,006) Total operatin

  14. Slide 14: Key figures - high level of activity

    Key figures - high level of activity 30 000 20 000 Total operating expense Direct R&D expenses 15 000 20 000 10 000 10 000 5 000 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2023 2022 2023 2022 30 000 Operating expenses 22/23 Cash and short term financial investments 200 000 20 000 150 000 10 000 100 000 0 50 000 22

  15. Slide 15: Key figures – balance sheet

    Key figures – balance sheet Unaudited Unaudited Amounts in NOK thousands 31.03.2023 31.03.2022 31.12.2022 Assets Property, plant and equipment 126 35 124 Trade and other receivables 7,073 7,242 6,735 Short-term financial investments 51,314 0 50,606 Cash and cash equivalents 75,057 180,666 94,552 Tot

  16. Slide 16: Outlook

    Outlook

  17. Slide 17: Key objectives moving forward

    Key objectives moving forward Clinical development ‒ Expand the clinical impact field for LTX-315 LTX-315 MONOTHERAPY and drive enrollment in the ATLAS-IT-05 Local treatment  Abscopal effect Phase II trial towards completion ‒ Continue to support Verrica Pharmaceuticals’ Phase II trial with LTX-315

  18. Slide 18: Q&A

    Q&A IR enquiries: ole.peter.nordby@lytixbiopharma.com

  19. Slide 19: Interim Financial Statements

    Interim Financial Statements

  20. Slide 20: Condensed Interim statement of profit and loss

    Condensed Interim statement of profit and loss Unaudited Unaudited Amounts in NOK thousands Q1 2023 Q1 2022 FY 2022 Revenue - - 1,409 Other operating income 375 1,509 15,864 Total operating income 375 1,509 17,273 Payroll and related expenses (5,289) (3,700) (21,133) Depreciation and amortization ex

  21. Slide 21: Condensed Interim statement of financial position

    Condensed Interim statement of financial position Unaudited Unaudited Amounts in NOK thousands 31.03.2023 31.03.2022 31.12.2022 Assets Non-current assets Property, plant and equipment 126 35 124 Total non-current assets 126 35 124 Current assets Trade and other receivables 7,073 7,242 6,735 Short-te

  22. Slide 22: Condensed Interim statement of cash flows

    Condensed Interim statement of cash flows Unaudited Unaudited Amounts in NOK thousands Q1 2023 Q1 2022 FY 2022 Cash flows from operating activities Loss for the period (19,673) (15,231) 56,006) Adjustments for: Depreciation of property, plant and equipment 14 - 30 Share-based payment expense 1,019 2

Lytix Biopharma — Q1 2023 Earnings Presentation on 6ix